Ghrelin level as a biomarker for knee osteoarthritis severity and appearance in HIV + patients

Ghrelin level as a biomarker for knee osteoarthritis severity and appearance in HIV + patients

Knee Osteoarthritis (KOA) is a multifactorial disease with several mechanisms to promote articular cartilage damage. New molecules, such as ghrelin, have been recently reported to participate in the pathogenesis and progression of KOA. In HIV + patients, arthralgias are the most frequent musculoskel...

Full description

Saved in:
Bibliographic Details
Published in:The knee Vol. 39; pp. 100 - 105
Main Authors: Arce-Rosas, Jorge I., González-Hernández, Luz A., Cabrera-Silva, Rodolfo I., Alvarez-Zavala, Monserrat, Sánchez-Reyes, Karina, Tafoya Arreguín, Gustavo A., Martinez Ruíz, Jose de Jesús, Cerda de la Torre, Rodrigo, Ramos-Solano, Moisés, Andrade-Villanueva, Jaime F.
Format: Journal Article
Language:English
Published: Netherlands Elsevier B.V 01-12-2022
Subjects:
Biomarker
Biomarkers
Cartilage, Articular - pathology
Ghrelin
HIV
HIV Infections - complications
HIV Infections - pathology
Humans
Knee
Knee Joint - pathology
Osteoarthritis
Osteoarthritis, Knee - pathology
Knee
Biomarker
OA
HIV
Ghrelin
KOA
Osteoarthritis
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Knee Osteoarthritis (KOA) is a multifactorial disease with several mechanisms to promote articular cartilage damage. New molecules, such as ghrelin, have been recently reported to participate in the pathogenesis and progression of KOA. In HIV + patients, arthralgias are the most frequent musculoskeletal manifestations, mainly affecting joints such as the knee. Also, it has been reported that HIV + patients have a reduction of ghrelin even with treatment compared to HIV- patients. However, there is no report in the literature evaluating ghrelin and KOA in the HIV + population. We aimed to evaluate whether serum ghrelin levels can function as a biomarker for OA in HIV + patients. We recruited 40 patients, 20 HIV+, and 20 HIV- controls, and grouped as follows: HIV+/KOA+; HIV+/KOA-; HIV-/KOA+; HIV-/KOA-. Clinical features were obtained during clinical visits. Peripheral blood samples were acquired to measure serum ghrelin levels. The HIV+/KOA + group significantly reduced serum ghrelin levels when compared with the other groups. Comparing the ghrelin levels with the patients’ nadir of CD4+ T-cells count, we identified a statistically significant negative correlation in the KOA- group (r = −0.80, P < 0.007). An ROC curve analysis, for the accuracy of ghrelin levels to identified HIV+/KOA + from HIV+/KOA- patients, found an area under the curve of 0.83 (95 % CI 0.65–0.10; P = 0.017), with a cut-off < 4026 pg/mL serum ghrelin levels, with a sensitivity of 0.62 (95 % CI 0.32–0.86), and a specificity of 0.10 (95 % CI 0.59–0.10). This study shows the potential use of ghrelin levels as a biomarker for KOA in the high-risk HIV population that should be further analyzed.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0968-0160
1873-5800
DOI:10.1016/j.knee.2022.08.005